Human ex-vivo action potential model for pro-arrhythmia risk assessment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
While current S7B/E14 guidelines have succeeded in protecting patients from QT-prolonging drugs, the absence of a predictive paradigm identifying pro-arrhythmic risks has limited the development of valuable drug programs. We investigated if a human ex-vivo action potential (AP)-based model could provide a more predictive approach for assessing pro-arrhythmic risk in man. Human ventricular trabeculae from ethically consented organ donors were used to evaluate the effects of dofetilide, d,l-sotalol, quinidine, paracetamol and verapamil on AP duration (APD) and recognized pro-arrhythmia predictors (short-term variability of APD at 90% repolarization (STV(APD90)), triangulation (ADP90-APD30) and incidence of early afterdepolarizations at 1 and 2 Hz to quantitatively identify the pro-arrhythmic risk. Each drug was blinded and tested separately with 3 concentrations in triplicate trabeculae from 5 hearts, with one vehicle time control per heart. Electrophysiological stability of the model was not affected by sequential applications of vehicle (0.1% dimethyl sulfoxide). Paracetamol and verapamil did not significantly alter anyone of the AP parameters and were classified as devoid of pro-arrhythmic risk. Dofetilide, d,l-sotalol and quinidine exhibited an increase in the manifestation of pro-arrhythmia markers. The model provided quantitative and actionable activity flags and the relatively low total variability in tissue response allowed for the identification of pro-arrhythmic signals. Power analysis indicated that a total of 6 trabeculae derived from 2 hearts are sufficient to identify drug-induced pro-arrhythmia. Thus, the human ex-vivo AP-based model provides an integrative translational assay assisting in shaping clinical development plans that could be used in conjunction with the new CiPA-proposed approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“More than half of all development programs are terminated due to safety-related issues, not anticipated by the preclinical studies (Cook et al., 2014).”
O'Hara, T., Virág, L., Varró, A., & Rudy, Y. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002061 · Cited by 1,196 · cited 1×
“Guo et al. (2011) showed that 0.1 μM dofetilide induced EADs in non-failing human myocytes at a pacing rate of 0.25 Hz (see also O'Hara et al., 2011).”
InfluentialComparison of Treatment Effects between Animal Experiments and Clinical Trials: Systematic Review
Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., Macleod, M., Mignini, L. E., Jayaram, P., & Khan, K. S. (2007) · BMJ · doi:10.1136/bmj.39048.407928.be · Cited by 827
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407 · cited 4×
“consistent with the known lack of pro-arrhythmic risk posed by these drugs (Gintant et al., 2016; Lawrence, Bridgland-Taylor, Pollard, Hammond, & Valentin, 2006; Redfern et al., 2003).”
InfluentialSelf-citationEwart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D. J., Geys, H., Jarvis, P., Ju, H., Leishman, D., Leong, L., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu198 · Cited by 77 · cited 1×
“While TQT studies have been relatively effective in preventing approval andmarketing of new drugs with strong pro-arrhythmic potential (Ewart et al., 2014; Vargas et al., 2015), the strategy has significant shortcomings.”
Cited by
Nguyen, N., Nguyen, W., Nguyenton, B., Ratchada, P., Page, G., Miller, P. E., Ghetti, A., & Abi-Gerges, N. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01073 · Cited by 75
Self-citationFunctional isolation, culture and cryopreservation of adult human primary cardiomyocytes
Zhou, B., Shi, X., Tang, X., Zhao, Q., Wang, L., Yao, F., Hou, Y., Wang, X., Feng, W., Wang, L., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01044-5 · Cited by 46
“The use of human primary cells and tissue to bridge the translation gaps in cardiac drug discovery and safety assessment is a burgeoning field of research.(20,21,62,63) Studies have reported the use of isolated human ventricular cardiomyocytes to simultaneously predict drug-induced inotropic and pro-arrhythmia risks,(…”
BackgroundAbi-Gerges, N., McMahon, C., Vargas, H., Sager, P., Chui, R., Stevens, D., Davila, J., Schaub, J. R., Wu, J. C., del Rio, C., et al. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106582 · Cited by 3
Self-citation
Metadata
- Authors
- Page, G., Ratchada, P., Miron, Y., Steiner, G., Ghetti, A., Miller, P. E., Reynolds, J. A., Wang, K., Greiter-Wilke, A., Polonchuk, L., Traebert, M., Gintant, G. A., & Abi-Gerges, N.
- Venue
- Journal of Pharmacological and Toxicological Methods
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 81
- Pages
- 183-195
- ISSN
- 1056-8719 (ISSN-L)
- OpenAlex
- W2407812843
- Cited by
- 41
- References
- 7
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human ex-vivo action potential model for pro-arrhythmia risk assessment. https://app.cochat.ai/papers/10.1016/j.vascn.2016.05.016
- The paper
- Page, G., Ratchada, P., Miron, Y., Steiner, G., Ghetti, A., Miller, P. E., Reynolds, J. A., Wang, K., Greiter-Wilke, A., Polonchuk, L., Traebert, M., Gintant, G. A., & Abi-Gerges, N. (2016). Human ex-vivo action potential model for pro-arrhythmia risk assessment. Journal of Pharmacological and Toxicological Methods. https://doi.org/10.1016/j.vascn.2016.05.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.